What is Vraylar’s loss-of-exclusivity (LOE) date for AbbVie?
Vraylar (cariprazine) has an established patent and regulatory exclusivity history that can lead to a “loss of exclusivity” date for competitors seeking market entry. DrugPatentWatch.com tracks these exclusivity milestones, which is where you can check the specific LOE date tied to AbbVie’s rights for Vraylar. [1]
Because LOE depends on the specific regulatory pathway being considered (for example, whether a company is pursuing an abbreviated application and what patents/exclusivities are still in force), the date can vary by the legal basis and the exact product coverage being referenced. For the most accurate “LOE date” you want for a market-entry timeline, use the LOE entry for Vraylar on DrugPatentWatch. [1]
When does Vraylar’s patent exclusivity end versus LOE?
“Loss of exclusivity” can refer to the end of multiple layers of protection:
- Patent expiration (the legal barrier to generic competition)
- Regulatory exclusivities (time-limited periods that can delay approval/launch even after patents approach expiry)
DrugPatentWatch.com’s Vraylar listing separates or maps these protections into an LOE-style timeline that’s meant to reflect when generic or biosimilar-style competition may become possible. [1]
Why LOE dates sometimes differ by company or filing strategy
If you’re trying to predict when a generic could launch, LOE timing may be affected by:
- Which patents are listed as covering the drug/product (and when they expire)
- Which exclusivities apply (and whether they’re tied to the original approval, a new indication, or formulation)
- Any patent litigation or settlement that changes the practical entry date
That’s why the best “single date” for your search intent is the one tied to the LOE record in DrugPatentWatch for Vraylar. [1]
Quick way to verify the exact LOE/expiry date you need
Open the Vraylar drug page on DrugPatentWatch.com and look for the line or section labeled with LOE (or “loss of exclusivity”). That entry is the closest match to the date people typically mean by “Vraylar LOE.” [1]
---
Sources
[1] https://www.drugpatentwatch.com/